1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Dalteparin Sodium Injection

Trade Name: Fragmin Injection
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as anticoagulant agent

2. HAZARDS IDENTIFICATION

Appearance: Clear, colorless to light yellow solution

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:
Short Term: Mild eye irritant in experimental animals. May produce allergic reactions following skin contact.

Known Clinical Effects: Clinical use of this drug has caused hemorrhage, gastrointestinal bleeding, increased bleeding time. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

EU Indication of danger: Not classified

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dalteparin Sodium (Heparin Sodium)</td>
<td>9041-08-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>5-12</td>
</tr>
</tbody>
</table>
4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.
7. HANDLING AND STORAGE

General Handling: Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.


Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Wear protective clothing when working with large quantities.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solution

Color: Colorless to pale straw-color

Molecular Formula: Mixture

Molecular Weight: Mixture

Solubility: Soluble: Water

pH: 5.0-7.5

Specific Gravity: 1.04

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride
Rat Oral LD50 3000 mg/kg
Mouse Oral LD50 4000 mg/kg

Dalteparin Sodium (Heparin Sodium)
Rat Oral LD50 > 5000 mg/kg
Mouse Oral LD50 > 5000 mg/kg
Mouse Intraperitoneal LD50 > 2500 mg/kg
Rat Intraperitoneal LD50 2500 mg/kg
Mouse Intravenous LD50 2800 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride
Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Dalteparin Sodium (Heparin Sodium)
Eye Irritation Rabbit Mild

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Dalteparin Sodium (Heparin Sodium)
Fertility and Embryonic Development Rat Subcutaneous 10 mg/kg/day NOAEL Fertility, Fetotoxicity
Embryo / Fetal Development Rat Intravenous 10,000 mg/kg/day LOAEL Fetotoxicity
Embryo / Fetal Development Rabbit Intravenous 2,500 mg/kg/day LOAEL Fetotoxicity

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

DALTEPARIN SODIUM INJECTION
14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:
Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications
WHMIS hazard class:
Non-controlled
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Sodium chloride

- Inventory - United States TSCA - Sect. 8(b): Listed
- Australia (AICS): Listed
- EU EINECS/ELINCS List: 231-598-3

Water

- Inventory - United States TSCA - Sect. 8(b): Listed
- Australia (AICS): Listed
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 231-791-2

Dalteparin Sodium (Heparin Sodium)

- Inventory - United States TSCA - Sect. 8(b): Listed
- Australia (AICS): Listed
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet